GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Inventories, Work In Process
Switch to:

Biogen (MEX:BIIB) Inventories, Work In Process

: MXN12,345 Mil (As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Biogen's work in process for the quarter that ended in Mar. 2023 was MXN12,345 Mil.


Biogen Inventories, Work In Process Historical Data

The historical data trend for Biogen's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Inventories, Work In Process
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 8,675.60 10,831.19 16,698.40 14,659.04

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Inventories, Work In Process Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13,053.65 14,209.34 15,508.67 14,659.04 12,345.32

Biogen Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.


Biogen (MEX:BIIB) Business Description

Biogen logo
Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines

Other Sources

Is Biogen Stock a Buy Now?

By Yahoo Finance 2023-01-26